Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages… Read more
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) - Total Assets
Latest total assets as of June 2025: CN¥6.56 Billion CNY
Based on the latest financial reports, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) holds total assets worth CN¥6.56 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total assets of CN¥6.56 Billion consist of 60.1% current assets and 39.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.0% |
| Accounts Receivable | CN¥1.69 Billion | 27.3% |
| Inventory | CN¥858.29 Million | 13.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥135.72 Million | 2.2% |
| Goodwill | CN¥1.12 Billion | 18.1% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's current assets represent 60.1% of total assets in 2024, a decrease from 87.2% in 2019.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, up from 8.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 27.3% of total assets.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Competitors by Total Assets
Key competitors of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ji Yao Holding Group Co Ltd
SHE:300108
|
China | CN¥1.43 Billion |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
China | CN¥9.84 Billion |
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
China | CN¥12.68 Billion |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
China | CN¥15.84 Billion |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥13.04 Billion |
|
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
SHE:300937
|
China | CN¥1.75 Billion |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
China | CN¥5.26 Billion |
|
Arich Enterprise Co Ltd
TWO:4173
|
Taiwan | NT$5.63 Billion |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd generates 0.85x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd generates $ 0.43 in net profit.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.31 | 2.29 |
| Quick Ratio | 0.94 | 1.02 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥596.47 Million | CN¥ 888.72 Million | CN¥ 1.50 Billion |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | CN¥6.18 Billion |
| Market Capitalization | $177.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2024)
The table below shows the annual total assets of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.18 Billion | +17.06% |
| 2023-12-31 | CN¥5.28 Billion | +34.24% |
| 2022-12-31 | CN¥3.93 Billion | +31.30% |
| 2021-12-31 | CN¥2.99 Billion | +35.99% |
| 2020-12-31 | CN¥2.20 Billion | +9.27% |
| 2019-12-31 | CN¥2.02 Billion | -- |